Firazyr Patient Registry Protocol (Icatibant Outcome Survey - IOS)
Phase of Trial: Phase IV
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Icatibant (Primary)
- Indications Angioedema; Hereditary angioedema
- Focus Adverse reactions
- Acronyms IOS
- Sponsors Shire
- 06 Mar 2017 Results (n=229) evaluating early versus late icatibant treatment, presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 19 Dec 2016 Planned number of patients changed from 790 to 3000.
- 19 Dec 2016 Planned End Date changed from 1 Dec 2020 to 1 Aug 2019.